Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to -$28.9 million.

  • Adma Biologics' Net Cash Flow fell 178028.63% to -$28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.3 million, marking a year-over-year decrease of 30176.89%. This contributed to the annual value of $51.8 million for FY2024, which is 24727.04% up from last year.
  • Adma Biologics' Net Cash Flow amounted to -$28.9 million in Q3 2025, which was down 178028.63% from $18.7 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Net Cash Flow registered a high of $51.6 million during Q4 2022, and its lowest value of -$31.5 million during Q1 2025.
  • Over the past 5 years, Adma Biologics' median Net Cash Flow value was -$6.0 million (recorded in 2024), while the average stood at $287578.9.
  • As far as peak fluctuations go, Adma Biologics' Net Cash Flow skyrocketed by 74144.37% in 2024, and later tumbled by 178028.63% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Net Cash Flow stood at $16.7 million in 2021, then soared by 209.48% to $51.6 million in 2022, then plummeted by 144.18% to -$22.8 million in 2023, then surged by 172.09% to $16.4 million in 2024, then plummeted by 275.79% to -$28.9 million in 2025.
  • Its Net Cash Flow was -$28.9 million in Q3 2025, compared to $18.7 million in Q2 2025 and -$31.5 million in Q1 2025.